You are here

First PI3K Inhibitor Approved for Breast Cancer

Data Show Drug Significantly Prolongs Survival

The FDA has approved alpelisib tablets (Piqray, Novartis), used in combination with fulvestrant, for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

In addition, the agency approved the therascreen PIK3CA RGQ PCR Kit (QIAGEN Manchester, Ltd.), a companion diagnostic test for detecting the PIK3CA mutation in a tissue and/or liquid biopsy.

Alpelisib’s efficacy was studied in the randomized SOLAR-1 study of 572 postmenopausal women and men with HR-positive, HER2-negative, advanced or metastatic breast cancer whose cancer had progressed while on or after receiving an aromatase inhibitor. Results showed that adding alpelisib to fulvestrant significantly prolonged progression-free survival (median, 11 months vs. 5.7 months) in patients whose tumors had a PIK3CA mutation.

Common side effects include high blood-sugar levels, creatinine increase, diarrhea, rash, decreased lymphocyte count, elevated liver enzymes, nausea, fatigue, low red-blood cell count, increased lipase, decreased appetite, stomatitis, and vomiting, among others.

The FDA granted alpelisib a priority review designation.

Source: FDA, May 24, 2019

Recent Headlines

Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
So far in January, the increases average 5%
Fast-acting insulin aspart may simplify mealtime dosing
Simple change in dosage and route may improve a century-old vaccine
Neurodevelopmental deficits detected in Colombian toddlers